Harnessing Inflammation Resolving-based Therapeutic Agents to Treat Pulmonary Viral Infections: What Can the Future Offer to COVID-19?

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2020 Jun 20

PMID 32557557

Citations 14

Authors

Lirlandia P Sousa

Vanessa Pinho

Mauro M Teixeira

Affiliations

Soon will be listed here.

Abstract

Inflammation is generally accepted as a component of the host defence system and a protective response in the context of infectious diseases. However, altered inflammatory responses can contribute to disease in infected individuals. Many endogenous mediators that drive the resolution of inflammation are now known. Overall, mediators of resolution tend to decrease inflammatory responses and provide normal or greater ability of the host to deal with infection. In the lung, it seems that pro-resolution molecules, or strategies that promote their increase, tend to suppress inflammation and lung injury and facilitate control of bacterial or viral burden. Here, we argue that the demonstrated anti-inflammatory, pro-resolving, anti-thrombogenic and anti-microbial effects of such endogenous mediators of resolution may be useful in the treatment of the late stages of the disease in patients with COVID-19.

Citing Articles

Intranasal liposomal angiotensin-(1-7) administration reduces inflammation and viral load in the lungs during SARS-CoV-2 infection in K18-hACE2 transgenic mice.

Mendes S, Guimaraes L, Costa P, Fernandez C, Figueiredo M, Teixeira M Antimicrob Agents Chemother. 2024; 68(12):e0083524.

PMID: 39470198 PMC: 11619396. DOI: 10.1128/aac.00835-24.

Angiotensin-(1-7) decreases inflammation and lung damage caused by betacoronavirus infection in mice.

Lima E, Carvalho A, Zaidan I, Monteiro A, Cardoso C, Lara E Inflamm Res. 2024; 73(11):2009-2022.

PMID: 39292270 DOI: 10.1007/s00011-024-01948-8.

A single dose of angiotensin-(1-7) resolves eosinophilic inflammation and protects the lungs from a secondary inflammatory challenge.

Magalhaes G, Gregorio J, Beltrami V, Felix F, Oliveira-Campos L, Bonilha C Inflamm Res. 2024; 73(6):1019-1031.

PMID: 38656426 DOI: 10.1007/s00011-024-01880-x.

The Multifaceted Role of Annexin A1 in Viral Infections.

Resende F, Araujo S, Tavares L, Teixeira M, Costa V Cells. 2023; 12(8).

PMID: 37190040 PMC: 10137178. DOI: 10.3390/cells12081131.

Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators.

Yasmeen N, Selvaraj H, Lakhawat S, Datta M, Sharma P, Jain A Biochem Pharmacol. 2023; 209:115437.

PMID: 36731803 PMC: 9884647. DOI: 10.1016/j.bcp.2023.115437.

References

Perretti M, Leroy X, Bland E, Montero-Melendez T . Resolution Pharmacology: Opportunities for Therapeutic Innovation in Inflammation. Trends Pharmacol Sci. 2015; 36(11):737-755. DOI: 10.1016/j.tips.2015.07.007. View

Trentin P, Ferreira T, Arantes A, Ciambarella B, Cordeiro R, Flower R . Annexin A1 mimetic peptide controls the inflammatory and fibrotic effects of silica particles in mice. Br J Pharmacol. 2015; 172(12):3058-71. PMC: 4459023. DOI: 10.1111/bph.13109. View

Feehan K, Gilroy D . Is Resolution the End of Inflammation?. Trends Mol Med. 2019; 25(3):198-214. DOI: 10.1016/j.molmed.2019.01.006. View

Cilloniz C, Pantin-Jackwood M, Ni C, Goodman A, Peng X, Proll S . Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection. J Virol. 2010; 84(15):7613-24. PMC: 2897611. DOI: 10.1128/JVI.00553-10. View

Sugimoto M, Ribeiro A, Costa B, Vago J, Lima K, Carneiro F . Plasmin and plasminogen induce macrophage reprogramming and regulate key steps of inflammation resolution via annexin A1. Blood. 2017; 129(21):2896-2907. PMC: 5445571. DOI: 10.1182/blood-2016-09-742825. View

Magalhaes G, Barroso L, Reis A, Rodrigues-Machado M, Gregorio J, Motta-Santos D . Angiotensin-(1-7) Promotes Resolution of Eosinophilic Inflammation in an Experimental Model of Asthma. Front Immunol. 2018; 9:58. PMC: 5797293. DOI: 10.3389/fimmu.2018.00058. View

Oliveira L, Souza-Testasicca M, Vago J, Figueiredo A, Canavaci A, Perucci L . Annexin A1 Is Involved in the Resolution of Inflammatory Responses during Infection. J Immunol. 2017; 198(8):3227-3236. DOI: 10.4049/jimmunol.1602028. View

Sencio V, Barthelemy A, Tavares L, G Machado M, Soulard D, Cuinat C . Gut Dysbiosis during Influenza Contributes to Pulmonary Pneumococcal Superinfection through Altered Short-Chain Fatty Acid Production. Cell Rep. 2020; 30(9):2934-2947.e6. DOI: 10.1016/j.celrep.2020.02.013. View

Kim N, Lannan K, Thatcher T, Pollock S, Woeller C, Phipps R . Lipoxin B Enhances Human Memory B Cell Antibody Production via Upregulating Cyclooxygenase-2 Expression. J Immunol. 2018; 201(11):3343-3351. PMC: 6246818. DOI: 10.4049/jimmunol.1700503. View

10.

Wang H, Anthony D, Yatmaz S, Wijburg O, Satzke C, Levy B . Aspirin-triggered resolvin D1 reduces pneumococcal lung infection and inflammation in a viral and bacterial coinfection pneumonia model. Clin Sci (Lond). 2017; 131(18):2347-2362. DOI: 10.1042/CS20171006. View

11.

Garcia C, Guabiraba R, Soriani F, Teixeira M . The development of anti-inflammatory drugs for infectious diseases. Discov Med. 2010; 10(55):479-88. View

12.

Tavares L, Garcia C, Vago J, Queiroz-Junior C, Galvao I, David B . Inhibition of Phosphodiesterase-4 during Pneumococcal Pneumonia Reduces Inflammation and Lung Injury in Mice. Am J Respir Cell Mol Biol. 2015; 55(1):24-34. DOI: 10.1165/rcmb.2015-0083OC. View

13.

Rago F, Melo E, Kraemer L, Galvao I, Cassali G, Santos R . Effect of preventive or therapeutic treatment with angiotensin 1-7 in a model of bleomycin-induced lung fibrosis in mice. J Leukoc Biol. 2019; 106(3):677-686. DOI: 10.1002/JLB.MA1218-490RR. View

14.

Ampomah P, Moraes L, Lukman H, Lim L . Formyl peptide receptor 2 is regulated by RNA mimics and viruses through an IFN-β-STAT3-dependent pathway. FASEB J. 2017; 32(3):1468-1478. DOI: 10.1096/fj.201700584RR. View

15.

Galvao I, Tavares L, Correa R, Fachi J, Rocha V, Rungue M . The Metabolic Sensor GPR43 Receptor Plays a Role in the Control of Infection in the Lung. Front Immunol. 2018; 9:142. PMC: 5826235. DOI: 10.3389/fimmu.2018.00142. View

16.

Bandeira-Melo C, Bonavita A, Diaz B, E Silva P, Carvalho V, Jose P . A novel effect for annexin 1-derived peptide ac2-26: reduction of allergic inflammation in the rat. J Pharmacol Exp Ther. 2005; 313(3):1416-22. DOI: 10.1124/jpet.104.080473. View

17.

Shirey K, Lai W, Pletneva L, Karp C, Divanovic S, Blanco J . Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology. Mucosal Immunol. 2013; 7(3):549-57. PMC: 3965659. DOI: 10.1038/mi.2013.71. View

18.

Machado M, Tavares L, Souza G, Queiroz-Junior C, Ascencao F, Eustaquio Lopes M . The Annexin A1/FPR2 pathway controls the inflammatory response and bacterial dissemination in experimental pneumococcal pneumonia. FASEB J. 2020; 34(2):2749-2764. DOI: 10.1096/fj.201902172R. View

19.

Norris P, Libreros S, Chiang N, Serhan C . A cluster of immunoresolvents links coagulation to innate host defense in human blood. Sci Signal. 2017; 10(490). PMC: 5683850. DOI: 10.1126/scisignal.aan1471. View

20.

Tavares L, Teixeira M, Garcia C . The inflammatory response triggered by Influenza virus: a two edged sword. Inflamm Res. 2016; 66(4):283-302. DOI: 10.1007/s00011-016-0996-0. View